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Background: This study evaluated the durability of nitinol stent placement in high-risk patients with chronic critical limb
ischemia (CLI) and infrapopliteal lesions after suboptimal balloon angioplasty.
Methods: Between January 2006 and January 2009, 53 high-risk patients (24 women; mean age, 71.8  5.1 years) with
CLI underwent infragenicular stent placement with a 4F sheath-compatible self-expanding nitinol stent. Patients had
three or more serious cardiopulmonary comorbidities, including chronic obstructive pulmonary disease, congestive heart
failure, coronary artery occlusive disease, American Society of Anesthesiologists score>3, previous myocardial infarction,
coronary stent or bypass, or infection after peripheral revascularization. Endovascular therapy was performed in 30
stenoses and 23 occlusions in 53 patients. The mean stenosis length was 5.5 1.9 cm. The mean occlusion length was 6.5
2.9 cm. The mean follow-up was 24.1  7.3 months and consisted of clinical examination, ankle-brachial index (ABI)
measurements, and duplex ultrasound imaging. Digital subtraction angiography was performed if restenosis or reocclu-
sion was suspected.
Results: The technical success rate was 98.1%. The 24-month cumulative primary patency rate was 75.5%. During the
follow-up, two patients underwent successful repeat angioplasty, and four patients required crural bypass. The 24-month
secondary patency and freedom from amputation rates were 88.7% and 88.7%, respectively. The mean ABI increased
significantly at 12 and 24 months (P < .001). Risk stratification to detect predictors that influenced the patency rate
showed that proximal lesions had significant better patency than distal crural lesions (83.3% vs 65.2%, P  .04). The
morphology of the lesions (stenoses vs occlusions, P .88) did not seem to influence primary patency. Four patients died
from nonprocedure-related causes during the follow-up, including lung cancer, myocardial infarction, and glioblastoma
multiforme. No procedure-related deaths were recorded.
Conclusions: The 2-year outcome of our series underscores the value of infrapopliteal nitinol stent placement as a durable
bailout treatment option in high-risk CLI patients with suboptimal angioplasty. ( J Vasc Surg 2010;52:356-61.)The application of percutaneous techniques for the
treatment of peripheral arterial occlusive disease has gained
widespread interest during the last decade. Together with
the development of new endovascular tools and increasing
operator experience, minimally invasive percutaneous ther-
apy plays an important role at many institutions. The By-
pass versus Angioplasty in Severe Ischaemia of the Leg
(BASIL) Trial concluded that lower limb bypass and bal-
loon angioplasty were associated with broadly similar mid-
term outcomes for amputation-free survival in patients with
chronic limb ischemia due to infrapopliteal occlusive ath-
erosclerosis.1
Numerous reports2-10 have attempted to evaluate the
role of bare-metal, metal-absorbable, carbofilm-coated, or
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356drug-eluting stent implantation in distal popliteal and infr-
apopliteal arteries but have provided scant information8
about the midterm and long-term outcomes. We recently
published our preliminary experience with infragenicular
bare nitinol stent placement, showing safety and feasibility
of the device.11 The present study assessed the durability
and clinical value of self-expanding stents in the treatment
of high-risk patients with critical limb ischemia (CLI) after
a mean follow-up of 2 years.
METHODS
Our institution does not require ethical approval for
this type of report.
Patients. Between January 2006 and January 2009,
53 consecutive high-risk patients (24 women), who had a
mean age of 71.8  5.1 years, underwent infragenicular
stent placement of below-knee lesions, including popliteal
(PIII segment) and crural arteries. In the same period, 119
patients with CLI underwent infragenicular angioplasties,
242 patients underwent crural bypass surgery, and 43 un-
derwent other endovascular techniques. All patients
showed suboptimal angioplasty, consisting of 30% resid-
ual stenosis, elastic recoil, or flow-limiting dissection. CLI
was documented as categories 4, 5, or 6 according to
Rutherford’s classification, evidenced by rest pain, nonheal-
ing ulceration or gangrene plus evidence of diffuse pedal
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metatarsal pulse volume recording flat or barely pulsatile,
toe pressure 30 mm Hg.
Baseline patient demographics are presented in the
Table. All patients were considered as high-risk patients, as
defined by the coexistence of at least three or more serious
cardiopulmonary comorbidities, including chronic ob-
structive pulmonary disease, congestive heart failure, coro-
nary artery occlusive disease, previous myocardial infarc-
tion, coronary stent or bypass, preexisting renal failure, or
American Society of Anesthesiologists score 3.
Endovascular therapy was performed in 30 stenoses
and 23 occlusions in 53 patients. The mean stenosis length
was 5.5  1.9 cm (range, 2.4-7.1 cm), and the mean
occlusion length was 6.5  2.9 cm (range, 3.0-7.6 cm).
The aim of therapy was to achieve adequate patency in at
least one below-knee vessel and the overall improvement of
runoff to the ankle. The inflow of the popliteal artery was
unlimited. Concomitant supragenicular lesions were re-
stored by balloon percutaneous transluminal angioplasty
(PTA) or previous stenting of the below-knee intervention.
This was necessary in 41 patients (77.3%) due to the
multilevel nature of the disease, including the iliac artery
PTA in 9, iliac artery stenting in 10, superficial femoral
artery PTA in 16, and superficial femoral artery stent place-
ment in 19.
No clopidogrel loading was used before an interven-
tion. The anticoagulation regimen after the intervention
included 6 weeks of clopidogrel (75 mg daily) and lifelong
acetylsalicylic acid (100 mg daily).
Intervention. Local anesthesia (10 mL of 1% Xylo-
caine [Astra Pharmaceutical, Worcester, Mass]) was infil-
trated, the contralateral common femoral artery (CFA) was
punctured, and a 5F sheath was introduced in 42 cases
(79.2%). An ipsilateral access was performed in 11 cases
(20.8%) who had undergone previous arterial reconstruc-
Table. Patient demographic data
Variable
Patients
(n  53)
Rutherford category, No. (%)
4 22 (41.5)
5 31 (58.5)
Age, mean  SD, y 71.8  5.1
Sex, No. (%)
Male 29 (54.7)
Female 24 (45.2)
High-risk factors, No. (%)
Arterial hypertension 33 (62.2)
Cardiac insufficiency (NYHA I) 12 (22.6)
Preexisting renal insufficiency 15 (28.3)
Previous MI, coronary stent, or bypass 19 (35.8)
ASA, 3 45 (84.9)
3 risk factors 53 (100)
ASA, American Society of Anesthesiologists; MI, myocardial infarction;
NYHA, New York Heart Association functional class; SD, standard devia-
tion.tion of the contralateral CFA (n 6) or who had unsuitablemorphology of the iliac artery for crossover maneuver (ie,
steep aortic bifurcation in 3, tortuous or calcified iliac
arteries in 2).
A pigtail angiographic catheter was advanced in the
renal aortic segment, and an angiogram of the aortoiliac
and peripheral arteries was performed. After a crossover
maneuver with the pigtail catheter and introduction of
0.035-inch guidewire (Radifocus, Terumo Europe, Leu-
ven, Belgium), the 5F sheath was changed with a long
(45- or 90-cm) flexible 6F sheath (Destination, Terumo
Europe). Heparin (5000 IU) was routinely given intra-
operatively.
Low-profile balloon PTA catheters (Submarine and
Amphirion, Invatec, Roncadelle, Italy) were used, with
diameters of 2 to 4 mm and lengths of 20 to 80 mm
determined by the size of the relevant artery. Balloon
pressure ranged from 6 to 16 atm, and balloon inflation was
performed at the target lesion.
Of the 68 stents that were implanted (mean, 1.2 0.4
per patient), 54 were applied into the crural arteries and 14
were placed into the distal popliteal artery. A single stent
was implanted in 40 of the 53 patients (75.5%). Stent
overlapping was necessary in 13 (24.5%) due to extensive
flow-limiting dissection.
The Xpert stent system (Abbott Vascular, Redwood
City, Santa Clara, Calif) was used. This self-expanding
nitinol stent, specifically designed for infragenicular lesions
of small vessels, has a diameter of 3 to 8 mm and a length of
20 to 60 mm and is compatible with a 4F sheath. Recently,
the stent has also become available in a 120-mm length.
Implantation of the Xpert stent system was not possible in
one patient due to friction caused by extensive atheroscle-
rosis of the anterior tibial artery, and a Chromis Deep stent
(Invatec, Roncadelle, Italy) was successfully implanted.
The Chromis Deep stent is cobalt chromium balloon-
expandable stent with closed-cell design.
Complications during the intervention and in the first
24 hours after were documented. All patients were assessed
by ankle-brachial index (ABI) measurements and by color-
flow and duplex Doppler ultrasound (DUS) imaging be-
fore hospital discharge, at 3, 6 and 12 months, and yearly
thereafter. Digital subtraction angiography was performed
if duplex DUS imaging identified restenosis or reocclusion.
Mean follow-up was 24.1  7.3 months.
End point definition. Primary end points of our
study were 24-month patency and technical, hemody-
namic, and clinical success and limb salvage. Secondary end
points were minor and major complications. Anatomic
primary patency was defined as lack of recurrent occlusion
50% in diameter reduction of the treated segment, doc-
umented by color-flow and duplex DUS imaging or digital
subtraction angiography. Technical success was deter-
mined as 30% of final residual stenosis measured at the
narrowest point of the treated vascular segment. To docu-
mented hemodynamic success, resting ABI measurements
at baseline, at 12 and 24 hours after endovascular treat-
ment, and at the latest follow-up were performed. The
short and long-term ABI-based definition of success was
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baseline measurement. Clinical success was defined by
sustained clinical improvement, as categorized by Ruth-
erford guidelines and included hemodynamic and clini-
cal measures.
Statistical analysis. Descriptive data are presented as
means  standard deviation and range, if appropriate;
nominal data are given as counts and percentages. Statisti-
cal analysis was done with SPSS 13.0 software (SPSS Inc,
Chicago, Ill). Continuous quantitative data were compared
with the nonparametric two-sample Wilcoxon signed-rank
test as appropriate. The persistence of crural arteries’
patency during the follow-up was evaluated by Kaplan-
Meier life-table analysis. Statistical significance was taken
at P  .05.
RESULTS
The technical success rate was 98.1% (52 of 53 cases).
No early (30-day) morbidity or mortality was noted. The
cumulative primary patency rate at 24 months was 75.5%
(Fig 1). Two patients underwent successful repeat angio-
plasty at 5 and 9 months due to in-stent restenosis (70%)
with relevant limitation of the pain-free walking distance.
No evidence of stent fracture was noted in these patients.
Four patients presented with rest pain with angiographic
evidence of insufficient run-in to the treated segment and
therefore were treated by crural bypasses.
All patients showed symptom improvement, including
healing of the ulceration for the patients with trophic
lesions. The ABI index significantly increased at 24 hours,
from 0.28  0.07 to 0.86  0.12 (P  .001). A sustained
improvement of the ABI index has been shown at 12 (0.78
0.3, P.001) and 24 months (0.82  0.3, P .001). The
amputation-free interval for the patients with CLI was
88.7% for the entire follow-up (Fig 2). Six patients under-
went a limb amputation of the treated extremity after
occlusion of the stents and no possibility of an alternative
Fig 1. Cumulative primary and secondary patency rat
high-risk patients with chronic critical limb ischemia.revascularization.The risk stratification to detect predictors that influence
the patency rate showed that proximal lesions had 83.4%
patency compared with 62.2% for distal crural lesions (P 
.04); however, the morphology of the lesions (stenoses vs
occlusions, P  .88) did not seem to influence the primary
patency (Figs 3 and 4).
The overall complication rate was 3.7% (n  2). False
aneurysms developed in two patients at the puncture site in
the groin after antegrade access and use of a 6F sheath. A
surgical evacuation of the hematomas and revision of the
common femoral access was necessary. No cardiorespira-
tory complications, such as myocardial infarction, decom-
pensated respiratory insufficiency, or impairment of the
renal function leading to hemodialysis were noted in this
series. No procedure-related deaths occurred during the
follow-up period; however, four patients died from causes
that were not related to the procedure, including lung
cancer, myocardial infarction, and glioblastoma multi-
forme.
DISCUSSION
The present study demonstrates the 2-year results of
one of the largest series in the literature, to our knowledge,
concerning stent angioplasty of the crural arteries in pa-
tients with CLI and suboptimal balloon angioplasty results.
The 24-month primary and secondary patency rates were
75.5% and 88.7%, respectively. The risk stratification to
detect predictors that influence the patency rate showed
that proximal lesions had significantly better patency than
the distal crural lesions (83.3% vs 65.2%, P  .04) in
contrast with the morphology of the lesions (stenosis vs
occlusions, P  .88).
The flexibility of the device is beneficial, especially for
the infragenicular lesions of the third popliteal segment and
proximal part of the crural arteries. This technical point
contributes to optimizing the vessel lumen and minimizing
the flow disturbances, even in tortuous anatomy. The
e shown for self-expanding stents below the knee fores arlength of the device of up to 120 mm allows the treatment
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arteries. The described stent system is the first to be mar-
keted worldwide with a crossing profile of 4F. This is
beneficial when coexisting iliac or superficial femoris arter-
ies lesions needed 6F approach, as in the majority of our
patients, are absent or when lesions of the superficial fem-
Fig 2. The cumulative limb salvage rate is shown for 5
below-knee stenting.
Fig 3. Cumulative primary and secondary patency rat
high-risk patients with chronic critical limb ischemia.oral arteries need a 6F approach, as in most of our patients.The positive effect of nitinol stents in the femoropop-
liteal arteries in terms of significantly improving of patency
rates compared with stainless steel stents or balloon angio-
plasty with optional stenting has already been described.12-14
For the moment, the literature provides scant but encourag-
ing information about the utility and effectiveness of bare
gh-risk patients with chronic critical limb ischemia and
e shown for proximal vs distal below-knee lesions for3 hies arnitinol stent placement in below-knee lesions.15 Kickuth et
b isc
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teal and crural arteries by the same Xpert system in 16 CLI
patients and documented a limb salvage rate of 100% and
marked clinical improvement of 80%. The results from their
study as well as our study reflect an excellent pushability and
trackability of the stent, which has low strut profile that is
specifically designed for small vessels.
Numerous reports have evaluated the role of drug-
eluting balloon-expandable stents in the crural arter-
ies.15,16 Despite the encouraging results with the use of
drug-eluting stents below the knee, a major concern re-
mains the length of the stents and their cost. Most of the
infrapopliteal lesions are long, and therefore, the application of
several short to 20-mm drug-eluting stents is cost-ineffective.
Moreover, balloon-expandable stents are not flexible and can
collapse or fracture in the infrapopliteal segment.17,18
Drawbacks of the Xpert stent system are the poor
visibility and moderate radial force, especially in patients
with severe calcification of the vessel lumen. Therefore, in
one patient with focal tortuous calcification and high fric-
tion in the middle segment of the tibial artery, we used a
balloon-expandable stent to treat the lesion. Moreover,
below-knee stent placement is only possible in cases of
unlimited supragenicular inflow. This condition is often
absent due to the multisegmental nature of the disease and
requires simultaneous endovascular treatment that can of-
ten be hazardous, especially in TransAtlantic Inter-Society
Consensus D lesions.8
Limitations of the present study include the retrospec-
tive, nonrandomized data analysis without a control group.
Although this series reflects durability, any comparison
Fig 4. Cumulative primary and secondary patency ra
occlusions, for high-risk patients with chronic critical limwith crural balloon PTA or bypass seems premature for themoment. However, in high-risk patients with critical pe-
ripheral arterial disease who are unfit for crural bypass
surgery, below-knee stent-supported angioplasty can be
considered as the first-choice bailout procedure.
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